335 related articles for article (PubMed ID: 32915435)
1. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
Falcetta P; Orsolini F; Benelli E; Agretti P; Vitti P; Di Cosmo C; Tonacchera M
Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
[TBL] [Abstract][Full Text] [Related]
2. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
Araujo-Castro M; Parra Ramírez P; Martín Rojas-Marcos P; García Centeno R; Gracia Gimeno P; Tomé Fernández-Ladreda M; Sampedro Núñez MA; Higueruela C; Robles Lázaro C
Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; Cuesta Hernández M; Sampedro Núñez MA; Marazuela M
Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
[TBL] [Abstract][Full Text] [Related]
4. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
Tsagarakis S; Kokkoris P; Roboti C; Malagari C; Kaskarelis J; Vlassopoulou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 May; 48(5):627-33. PubMed ID: 9666875
[TBL] [Abstract][Full Text] [Related]
5. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
Tsagarakis S; Roboti C; Kokkoris P; Vasiliou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 Aug; 49(2):165-71. PubMed ID: 9828902
[TBL] [Abstract][Full Text] [Related]
6. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.
Rossi R; Tauchmanova L; Luciano A; Di Martino M; Battista C; Del Viscovo L; Nuzzo V; Lombardi G
J Clin Endocrinol Metab; 2000 Apr; 85(4):1440-8. PubMed ID: 10770179
[TBL] [Abstract][Full Text] [Related]
7. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
[TBL] [Abstract][Full Text] [Related]
8. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases.
Brox-Torrecilla N; García Cano AM; Valderrábano P; Quintero Tobar A; Escobar-Morreale HF; Araujo-Castro M
Endocrine; 2023 Sep; 81(3):484-491. PubMed ID: 37212980
[TBL] [Abstract][Full Text] [Related]
10. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
Araujo-Castro M; Hanzu FA; Pascual-Corrales E; García Cano AM; Marchan M; Escobar-Morreale HF; Valderrabano P; Casals G
Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study.
Araujo-Castro M; Casals G; Hanzu FA; Pascual-Corrales E; García Cano AM; Lanza VF; Luis Del Rey Mejías Á; Marchan M; Escobar-Morreale HF; Valderrabano P
Clin Endocrinol (Oxf); 2023 Feb; 98(2):165-176. PubMed ID: 35973974
[TBL] [Abstract][Full Text] [Related]
12. Adrenal incidentaloma as a novel independent predictive factor for periodontitis.
Rodrigues MO; Moraes AB; de Paula MP; Pereira VA; Leão ATT; Vieira Neto L
J Endocrinol Invest; 2021 Nov; 44(11):2455-2463. PubMed ID: 33788166
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients' stratification by body mass index and age.
Podbregar A; Janez A; Goricar K; Jensterle M
BMC Endocr Disord; 2020 Jul; 20(1):118. PubMed ID: 32736549
[TBL] [Abstract][Full Text] [Related]
14. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
Araujo-Castro M; Mínguez Ojeda C; Sánchez Ramírez MN; Gómez Dos Santos V; Pascual-Corrrales E; Fernández-Argüeso M
Endocrine; 2022 Oct; 78(1):142-150. PubMed ID: 35751779
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.
Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884211
[TBL] [Abstract][Full Text] [Related]
16. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Tsagarakis S; Terzolo M; Tabarin A; Sahdev A; Newell-Price J; Pelsma I; Marina L; Lorenz K; Bancos I; Arlt W; Dekkers OM
Eur J Endocrinol; 2023 Jul; 189(1):G1-G42. PubMed ID: 37318239
[TBL] [Abstract][Full Text] [Related]
17. Subclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo M; Osella G; Alì A; Borretta G; Cesario F; Paccotti P; Angeli A
Clin Endocrinol (Oxf); 1998 Jan; 48(1):89-97. PubMed ID: 9509073
[TBL] [Abstract][Full Text] [Related]
18. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.
Androulakis II; Kaltsas GA; Kollias GE; Markou AC; Gouli AK; Thomas DA; Alexandraki KI; Papamichael CM; Hadjidakis DJ; Piaditis GP
J Clin Endocrinol Metab; 2014 Aug; 99(8):2754-62. PubMed ID: 24712565
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of patients with adrenal incidentalomas and cortisol autonomy: a German retrospective single center cohort study.
Remde H; Kranz S; Morell SM; Altieri B; Kroiss M; Detomas M; Fassnacht M; Deutschbein T
Front Endocrinol (Lausanne); 2023; 14():1123132. PubMed ID: 37223045
[TBL] [Abstract][Full Text] [Related]
20. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
Patrova J; Kjellman M; Wahrenberg H; Falhammar H
Endocrine; 2017 Nov; 58(2):267-275. PubMed ID: 28887710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
